Trial Outcomes & Findings for MN4000 for Treatment of CF and MND Patients in the Home Setting (NCT NCT03797677)
NCT ID: NCT03797677
Last Updated: 2024-08-07
Results Overview
The primary efficacy variable was patient and/or caregiver satisfaction with therapy, as evaluated using a Therapy Use Rating Questionnaire. The questionnaire was used to assess change in satisfaction or effectiveness on a variety of parameters. The satisfaction score was completed by the patient, if possible. Some of the patients in this study had Motor Neuron Disease. This disease can compromise the ability of the patient to interact and to respond to questions. In situations where patients could not respond, caregivers were asked to respond on their behalf.
COMPLETED
NA
10 participants
90 days
2024-08-07
Participant Flow
Participant milestones
| Measure |
Home Based Airway Clearance With Metaneb
Patients with CF and MND who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
|---|---|
|
Overall Study
STARTED
|
10
|
|
Overall Study
COMPLETED
|
10
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
MN4000 for Treatment of CF and MND Patients in the Home Setting
Baseline characteristics by cohort
| Measure |
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
n=5 Participants
Patients with CF who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
n=5 Participants
Patients with MND who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
Total
n=10 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
30.4 Years
STANDARD_DEVIATION 4.34 • n=99 Participants
|
65.2 Years
STANDARD_DEVIATION 16.54 • n=107 Participants
|
47.8 Years
STANDARD_DEVIATION 10.44 • n=206 Participants
|
|
Sex: Female, Male
Female
|
5 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
5 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
5 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
5 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
10 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
|
Race (NIH/OMB)
White
|
5 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
9 Participants
n=206 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Region of Enrollment
United States
|
5 participants
n=99 Participants
|
5 participants
n=107 Participants
|
10 participants
n=206 Participants
|
PRIMARY outcome
Timeframe: 90 daysThe primary efficacy variable was patient and/or caregiver satisfaction with therapy, as evaluated using a Therapy Use Rating Questionnaire. The questionnaire was used to assess change in satisfaction or effectiveness on a variety of parameters. The satisfaction score was completed by the patient, if possible. Some of the patients in this study had Motor Neuron Disease. This disease can compromise the ability of the patient to interact and to respond to questions. In situations where patients could not respond, caregivers were asked to respond on their behalf.
Outcome measures
| Measure |
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
n=5 Participants
Patients with CF who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
n=5 Participants
Patients with MND who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
|---|---|---|
|
Patient / Caregiver Satisfaction Scores
Difficulty of Use (Day 30) · Improved
|
0 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Difficulty of Use (Day 30) · Same
|
4 Participants
|
4 Participants
|
|
Patient / Caregiver Satisfaction Scores
Difficulty of Use (Day 30) · Worsened
|
1 Participants
|
1 Participants
|
|
Patient / Caregiver Satisfaction Scores
Difficulty of Use (Day 30) · Missing
|
0 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Missed Treatment (Day 30) · Improved
|
2 Participants
|
2 Participants
|
|
Patient / Caregiver Satisfaction Scores
Missed Treatment (Day 30) · Same
|
2 Participants
|
2 Participants
|
|
Patient / Caregiver Satisfaction Scores
Missed Treatment (Day 30) · Worsened
|
1 Participants
|
1 Participants
|
|
Patient / Caregiver Satisfaction Scores
Missed Treatment (Day 30) · Missing
|
0 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Bring up sputum (Day 30) · Improved
|
1 Participants
|
4 Participants
|
|
Patient / Caregiver Satisfaction Scores
Bring up sputum (Day 30) · Same
|
3 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Bring up sputum (Day 30) · Worsened
|
1 Participants
|
1 Participants
|
|
Patient / Caregiver Satisfaction Scores
Bring up sputum (Day 30) · Missing
|
0 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Shortness of breath (Day 30) · Improved
|
0 Participants
|
2 Participants
|
|
Patient / Caregiver Satisfaction Scores
Shortness of breath (Day 30) · Same
|
2 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Shortness of breath (Day 30) · Worsened
|
1 Participants
|
1 Participants
|
|
Patient / Caregiver Satisfaction Scores
Shortness of breath (Day 30) · Missing
|
2 Participants
|
2 Participants
|
|
Patient / Caregiver Satisfaction Scores
Lungs stay healthy (Day 30) · Improved
|
0 Participants
|
3 Participants
|
|
Patient / Caregiver Satisfaction Scores
Lungs stay healthy (Day 30) · Same
|
4 Participants
|
2 Participants
|
|
Patient / Caregiver Satisfaction Scores
Lungs stay healthy (Day 30) · Worsened
|
1 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Lungs stay healthy (Day 30) · Missing
|
0 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Ability to perform tasks (Day 30) · Improved
|
1 Participants
|
1 Participants
|
|
Patient / Caregiver Satisfaction Scores
Ability to perform tasks (Day 30) · Same
|
2 Participants
|
2 Participants
|
|
Patient / Caregiver Satisfaction Scores
Ability to perform tasks (Day 30) · Worsened
|
2 Participants
|
2 Participants
|
|
Patient / Caregiver Satisfaction Scores
Ability to perform tasks (Day 30) · Missing
|
0 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Difficulty of Use (Day 90) · Improved
|
0 Participants
|
1 Participants
|
|
Patient / Caregiver Satisfaction Scores
Difficulty of Use (Day 90) · Same
|
3 Participants
|
3 Participants
|
|
Patient / Caregiver Satisfaction Scores
Difficulty of Use (Day 90) · Worsened
|
2 Participants
|
1 Participants
|
|
Patient / Caregiver Satisfaction Scores
Difficulty of Use (Day 90) · Missing
|
0 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Missed Treatment (Day 90) · Improved
|
3 Participants
|
1 Participants
|
|
Patient / Caregiver Satisfaction Scores
Missed Treatment (Day 90) · Same
|
1 Participants
|
3 Participants
|
|
Patient / Caregiver Satisfaction Scores
Missed Treatment (Day 90) · Worsened
|
1 Participants
|
1 Participants
|
|
Patient / Caregiver Satisfaction Scores
Missed Treatment (Day 90) · Missing
|
0 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Bring up sputum (Day 90) · Improved
|
1 Participants
|
4 Participants
|
|
Patient / Caregiver Satisfaction Scores
Bring up sputum (Day 90) · Same
|
2 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Bring up sputum (Day 90) · Worsened
|
2 Participants
|
1 Participants
|
|
Patient / Caregiver Satisfaction Scores
Bring up sputum (Day 90) · Missing
|
0 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Shortness of breath (Day 90) · Improved
|
1 Participants
|
2 Participants
|
|
Patient / Caregiver Satisfaction Scores
Shortness of breath (Day 90) · Same
|
1 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Shortness of breath (Day 90) · Worsened
|
1 Participants
|
1 Participants
|
|
Patient / Caregiver Satisfaction Scores
Shortness of breath (Day 90) · Missing
|
2 Participants
|
2 Participants
|
|
Patient / Caregiver Satisfaction Scores
Lungs stay healthy (Day 90) · Improved
|
0 Participants
|
3 Participants
|
|
Patient / Caregiver Satisfaction Scores
Lungs stay healthy (Day 90) · Same
|
3 Participants
|
1 Participants
|
|
Patient / Caregiver Satisfaction Scores
Lungs stay healthy (Day 90) · Worsened
|
2 Participants
|
1 Participants
|
|
Patient / Caregiver Satisfaction Scores
Lungs stay healthy (Day 90) · Missing
|
0 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Ability to perform tasks (Day 90) · Improved
|
0 Participants
|
2 Participants
|
|
Patient / Caregiver Satisfaction Scores
Ability to perform tasks (Day 90) · Same
|
2 Participants
|
2 Participants
|
|
Patient / Caregiver Satisfaction Scores
Ability to perform tasks (Day 90) · Worsened
|
3 Participants
|
1 Participants
|
|
Patient / Caregiver Satisfaction Scores
Ability to perform tasks (Day 90) · Missing
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: 90 daysThe Therapy Use Rating Questionnaire is an assessment of patient/caregiver satisfaction with the therapy and their subjective assessment of the benefit of the therapy. The questionnaire was used to assess change in satisfaction or effectiveness on a variety of parameters. The satisfaction score was completed by the patient, if possible. Some of the patients in this study had Motor Neuron Disease This disease can compromise the ability of the patient to interact and to respond to questions. In situations where patients could not respond, caregivers were asked to respond on their behalf.
Outcome measures
| Measure |
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
n=5 Participants
Patients with CF who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
n=5 Participants
Patients with MND who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
|---|---|---|
|
Patient / Caregiver Satisfaction Scores
Effective (Day 30) · Much less
|
0 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Effective (Day 30) · Less
|
1 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Effective (Day 30) · Same
|
2 Participants
|
2 Participants
|
|
Patient / Caregiver Satisfaction Scores
Effective (Day 30) · More
|
1 Participants
|
2 Participants
|
|
Patient / Caregiver Satisfaction Scores
Effective (Day 30) · Much More
|
1 Participants
|
1 Participants
|
|
Patient / Caregiver Satisfaction Scores
Easy to perform (Day 30) · Much less
|
1 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Easy to perform (Day 30) · Less
|
1 Participants
|
2 Participants
|
|
Patient / Caregiver Satisfaction Scores
Easy to perform (Day 30) · Same
|
1 Participants
|
1 Participants
|
|
Patient / Caregiver Satisfaction Scores
Easy to perform (Day 30) · More
|
1 Participants
|
1 Participants
|
|
Patient / Caregiver Satisfaction Scores
Easy to perform (Day 30) · Much More
|
1 Participants
|
1 Participants
|
|
Patient / Caregiver Satisfaction Scores
Like to continue MN4000 (Day 30) · Much less
|
1 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Like to continue MN4000 (Day 30) · Less
|
0 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Like to continue MN4000 (Day 30) · Same
|
0 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Like to continue MN4000 (Day 30) · More
|
1 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Like to continue MN4000 (Day 30) · Much More
|
3 Participants
|
5 Participants
|
|
Patient / Caregiver Satisfaction Scores
Effective (Day 90) · Much less
|
0 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Effective (Day 90) · Less
|
1 Participants
|
1 Participants
|
|
Patient / Caregiver Satisfaction Scores
Effective (Day 90) · Same
|
3 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Effective (Day 90) · More
|
0 Participants
|
1 Participants
|
|
Patient / Caregiver Satisfaction Scores
Effective (Day 90) · Much More
|
1 Participants
|
3 Participants
|
|
Patient / Caregiver Satisfaction Scores
Easy to perform (Day 90) · Much less
|
2 Participants
|
1 Participants
|
|
Patient / Caregiver Satisfaction Scores
Easy to perform (Day 90) · Less
|
2 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Easy to perform (Day 90) · Same
|
0 Participants
|
1 Participants
|
|
Patient / Caregiver Satisfaction Scores
Easy to perform (Day 90) · More
|
1 Participants
|
1 Participants
|
|
Patient / Caregiver Satisfaction Scores
Easy to perform (Day 90) · Much More
|
0 Participants
|
2 Participants
|
|
Patient / Caregiver Satisfaction Scores
Like to continue MN4000 (Day 90) · Much less
|
1 Participants
|
1 Participants
|
|
Patient / Caregiver Satisfaction Scores
Like to continue MN4000 (Day 90) · Less
|
1 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Like to continue MN4000 (Day 90) · Same
|
0 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Like to continue MN4000 (Day 90) · More
|
1 Participants
|
0 Participants
|
|
Patient / Caregiver Satisfaction Scores
Like to continue MN4000 (Day 90) · Much More
|
2 Participants
|
4 Participants
|
SECONDARY outcome
Timeframe: 90 daysPopulation: CF and MND population
Adherence to the treatment regimen was calculated for each patient (number of minutes of therapy performed / number of minutes of therapy prescribed). The adherence percentage calculated for each study subject was then used to calculate the of Mean adherence to prescribed treatment regimen for the group or groups.
Outcome measures
| Measure |
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
n=5 Participants
Patients with CF who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
n=5 Participants
Patients with MND who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
|---|---|---|
|
Mean Percentage Adherence to Prescribed Treatment Regimen
|
97 Percentage of adherence to therapy
Interval 86.0 to 100.0
|
95 Percentage of adherence to therapy
Interval 89.7 to 99.5
|
SECONDARY outcome
Timeframe: 90 daysPopulation: MND subpopulation
MND patients only. The Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) is an instrument for evaluating the functional status of patients with Amyotrophic Lateral Sclerosis. It can be used to monitor functional change in a patient over time. It contains 10 distinct measures: * Speech * Salivation * Swallowing * Handwriting * Cutting food and handling utensils (with or without gastrostomy) * Dressing and hygiene * Turning in bed and adjusting bed clothes * Walking * Breathing * Climbing stairs These 10 parameters are scored on a scale of 0-4, based on the patients' ability to perform tasks. The minimum score is 0 and maximum 40.The higher the score the more function is retained.
Outcome measures
| Measure |
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
n=5 Participants
Patients with CF who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
Patients with MND who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
|---|---|---|
|
ALS-Functional Rating Scale (ALS-FRS)
Bulbar Sub-Score at Baseline
|
10.8 score on a scale
Standard Deviation 1.64
|
—
|
|
ALS-Functional Rating Scale (ALS-FRS)
Bulbar Sub-Score after 30 days of therapy
|
10.0 score on a scale
Standard Deviation 3.39
|
—
|
|
ALS-Functional Rating Scale (ALS-FRS)
Bulbar Sub-Score after 90 days of therapy
|
10.4 score on a scale
Standard Deviation 3.05
|
—
|
|
ALS-Functional Rating Scale (ALS-FRS)
Respiratory Sub-score at baseline
|
9.4 score on a scale
Standard Deviation 1.52
|
—
|
|
ALS-Functional Rating Scale (ALS-FRS)
Respiratory Sub-score after 30 days of therapy
|
10.2 score on a scale
Standard Deviation 1.10
|
—
|
|
ALS-Functional Rating Scale (ALS-FRS)
Respiratory Sub-score after 90 days of therapy
|
10.2 score on a scale
Standard Deviation 1.10
|
—
|
|
ALS-Functional Rating Scale (ALS-FRS)
Total Score at Baseline
|
33.6 score on a scale
Standard Deviation 6.84
|
—
|
|
ALS-Functional Rating Scale (ALS-FRS)
Total Score after 30 days of therapy
|
32.0 score on a scale
Standard Deviation 5.29
|
—
|
|
ALS-Functional Rating Scale (ALS-FRS)
Total Score after 90 days of therapy
|
32.2 score on a scale
Standard Deviation 5.07
|
—
|
SECONDARY outcome
Timeframe: 90 daysPopulation: Cystic Fibrosis Questionnaire - Revised (CFQ-R) administered on the CF patient subpopulation
CF patients only. The Cystic Fibrosis Questionnaire (CFQ) is a disease-specific instrument that measures health-related quality of life (HRQoL) for adolescents and adults with cystic fibrosis (CF) \> or = 14 years, consisting of 44 items on 12 generic and disease-specific scales. It offers 5 distinct 4-point Likert scales (e.g., always/often/ sometime/never). Scores for each HRQoL domain; after recoding, each item is summed to generate a domain score and standardized. Scores range from 0 to 100, with higher scores indicating better health.
Outcome measures
| Measure |
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
n=5 Participants
Patients with CF who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
Patients with MND who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
|---|---|---|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Eat domain after 30 days of therapy
|
100.0 Score on a scale
Standard Deviation 0.00
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Eat domain after 90 days of therapy
|
100.0 Score on a scale
Standard Deviation 0.00
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Physical domain at baseline
|
83.3 Score on a scale
Standard Deviation 19.54
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Physical domain after 30 days of therapy
|
78.3 Score on a scale
Standard Deviation 20.28
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Physical domain after 90 days of therapy
|
80.0 Score on a scale
Standard Deviation 17.78
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Role domain at baseline
|
80.0 Score on a scale
Standard Deviation 7.45
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Role domain after 30 days of therapy
|
90.0 Score on a scale
Standard Deviation 6.97
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Role domain after 90 days of therapy
|
86.7 Score on a scale
Standard Deviation 11.18
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Vitality domain at baseline
|
75.0 Score on a scale
Standard Deviation 16.67
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Vitality domain after 30 days of therapy
|
73.3 Score on a scale
Standard Deviation 6.97
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Vitality domain after 90 days of therapy
|
68.3 Score on a scale
Standard Deviation 13.69
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Emotion domain at baseline
|
89.3 Score on a scale
Standard Deviation 7.60
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Emotion domain after 30 days of therapy
|
81.3 Score on a scale
Standard Deviation 8.69
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Emotion domain after 90 days of therapy
|
86.7 Score on a scale
Standard Deviation 10.54
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Social domain at baseline
|
77.8 Score on a scale
Standard Deviation 14.70
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Social domain after 30 days of therapy
|
77.8 Score on a scale
Standard Deviation 13.61
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Social domain after 90 days of therapy
|
71.1 Score on a scale
Standard Deviation 13.83
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Body domain at baseline
|
97.8 Score on a scale
Standard Deviation 4.97
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Body domain after 30 days of therapy
|
91.1 Score on a scale
Standard Deviation 14.49
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Body domain after 90 days of therapy
|
91.1 Score on a scale
Standard Deviation 9.30
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Eat domain at baseline
|
97.8 Score on a scale
Standard Deviation 4.97
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Treat domain at baseline
|
55.6 Score on a scale
Standard Deviation 11.11
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Treat domain after 30 days of therapy
|
48.9 Score on a scale
Standard Deviation 9.94
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Treat domain after 90 days of therapy
|
46.7 Score on a scale
Standard Deviation 9.30
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Health domain at baseline
|
71.1 Score on a scale
Standard Deviation 6.09
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Health domain after 30 days of therapy
|
71.1 Score on a scale
Standard Deviation 6.09
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Health domain after 90 days of therapy
|
73.3 Score on a scale
Standard Deviation 14.91
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Weight domain at baseline
|
73.3 Score on a scale
Standard Deviation 36.51
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Weight domain after 30 days of therapy
|
100.0 Score on a scale
Standard Deviation 0.00
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Weight domain after 90 days of therapy
|
100.0 Score on a scale
Standard Deviation 0.00
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Respiratory domain at baseline
|
61.1 Score on a scale
Standard Deviation 23.90
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Respiratory domain after 30 days of therapy
|
61.1 Score on a scale
Standard Deviation 19.64
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Respiratory domain after 90 days of therapy
|
62.2 Score on a scale
Standard Deviation 10.69
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Digestion domain at baseline
|
84.4 Score on a scale
Standard Deviation 23.04
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Digestion domain after 30 days of therapy
|
93.3 Score on a scale
Standard Deviation 9.94
|
—
|
|
Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Digestion domain after 90 days of therapy
|
91.1 Score on a scale
Standard Deviation 4.97
|
—
|
SECONDARY outcome
Timeframe: 90 daysHospitalization and/or antibiotics for respiratory infection or complication. Exacerbations of pulmonary disease were defined as respiratory infections that resulted in the requirement for hospitalization and/or antibiotics to treat the respiratory infection or complication. Hospitalizations that are part of routine care (e.g. hospital admissions for annual "tune-up") or antibiotics that are part of the regular treatment regimen were not documented as exacerbations. Occurrence of exacerbation related hospitalization OR the necessity of a prescription for antibiotics qualify as worsening disease.
Outcome measures
| Measure |
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
n=10 Participants
Patients with CF who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
Patients with MND who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
|---|---|---|
|
Number of Participants With Exacerbation of Pulmonary Disease
Exacerbation of pulmonary disease at baseline
|
2 Participants
|
—
|
|
Number of Participants With Exacerbation of Pulmonary Disease
Exacerbation that required antibiotics but not hospitalization at Day 30
|
1 Participants
|
—
|
|
Number of Participants With Exacerbation of Pulmonary Disease
Exacerbations that required antibiotics at Day 90
|
3 Participants
|
—
|
SECONDARY outcome
Timeframe: 90 daysFEV1 is the actual volume measured in liters. Forced expiratory volume in one second (FEV1): The forced expiratory volume-one second is the total volume of air a patient exhales in the first second during maximal effort. Normal range is \>80%. The patient takes a full breath in and exhale as hard and fast as they can. FEV1 refers to the volume of air that an individual can exhale during a forced breath in the first 1 second. Decreasing percentage is associated with worsening / severe disease
Outcome measures
| Measure |
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
n=5 Participants
Patients with CF who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
n=5 Participants
Patients with MND who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
|---|---|---|
|
FEV1 (Actual)
FEV1 measure at baseline (Actual)
|
1.8 Liters
Standard Deviation 0.94
|
1.7 Liters
Standard Deviation 0.54
|
|
FEV1 (Actual)
FEV1 measure after 30 days of therapy (Actual)
|
1.9 Liters
Standard Deviation 1.05
|
1.6 Liters
Standard Deviation 0.71
|
|
FEV1 (Actual)
FEV1 measure after 90 days of therapy (Actual)
|
1.9 Liters
Standard Deviation 0.93
|
1.7 Liters
Standard Deviation 0.73
|
SECONDARY outcome
Timeframe: 90 daysFEV1 Percent Predicted (FEV1 % Predicted) is the actual volume exhaled in the first 1 second, divided by the "Normal" value for that actual value for a person of that age, gender, height and weight. A nomogram based on population norms provides a series of "Normal Values." FEV1: The forced expiratory volume-one second is the total volume of air a patient exhales in the first second during maximal effort. Normal range is \>80%. Decreasing percentage is associated with worsening / severe disease
Outcome measures
| Measure |
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
n=5 Participants
Patients with CF who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
n=5 Participants
Patients with MND who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
|---|---|---|
|
FEV1 (% Predicted)
FEV1 measure at baseline (% Predicted)
|
55.2 percentage of predicted normal
Standard Deviation 25.49
|
58.6 percentage of predicted normal
Standard Deviation 19.49
|
|
FEV1 (% Predicted)
FEV1 measure after 30 days of therapy (% Predicted)
|
58.8 percentage of predicted normal
Standard Deviation 27.81
|
57.8 percentage of predicted normal
Standard Deviation 28.42
|
|
FEV1 (% Predicted)
FEV1 measure after 90 days of therapy (% Predicted)
|
60.4 percentage of predicted normal
Standard Deviation 24.76
|
59.4 percentage of predicted normal
Standard Deviation 27.67
|
SECONDARY outcome
Timeframe: 90 daysPopulation: FVC and FEV1/FVC ratio are pulmonary function tests appropriate to assess lung function in patients with CF. These tests could not be physically performed by the patients in the MND population and thus these patients were not included in these analysis. For the MND population, SVC, SpO2, MIP, and PCF were performed instead of FVC and FEV1/FVC ratio. Hence, no data were collected from MND patients for this outcome measure.
FVC is the actual volume measured in liters. The functional vital capacity (FVC) is the total volume of air a patient exhales for the total duration of the test during maximal effort. Normal range is \>80%. Decreasing percentage is associated with worsening / severe disease. FVC was only done in CF subjects because performance of the test requires intact respiratory muscle function. CF patients have intact respiratory muscle function and can therefore perform this maneuver. Patients with Motor Neuron Disease suffer from progressive weakness of all muscles including the respiratory muscles. The test results for FVC are affected muscle weakness and are therefore not a valid representation of their pulmonary function.
Outcome measures
| Measure |
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
n=5 Participants
Patients with CF who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
Patients with MND who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
|---|---|---|
|
FVC (Actual)
FVC at baseline (Actual)
|
2.6 Liters
Standard Deviation 0.98
|
—
|
|
FVC (Actual)
FVC after 30 days of therapy (Actual)
|
2.6 Liters
Standard Deviation 1.08
|
—
|
|
FVC (Actual)
FVC after 90 days of therapy (Actual)
|
2.7 Liters
Standard Deviation 0.99
|
—
|
SECONDARY outcome
Timeframe: 90 daysPopulation: FVC and FEV1/FVC ratio are pulmonary function tests appropriate to assess lung function in patients with CF. These tests could not be physically performed by the patients in the MND population and thus these patients were not included in these analysis. For the MND population, SVC, SpO2, MIP, and PCF were performed instead of FVC and FEV1/FVC ratio. Hence, no data were collected from MND patients for this outcome measure.
FVC Percent Predicted (FVC % Predicted) is the actual volume exhaled in the first 1 second, divided by the "Normal" value for that actual value for a person of that age, gender, height and weight. A nomogram based on population norms provides a series of "Normal Values." The functional vital capacity is the total volume of air a patient exhales for the total duration of the test during maximal effort. Normal range is \>80%. Decreasing percentage is associated with worsening / severe disease. FVC was only done in CF subjects because performance of the test requires intact respiratory muscle function. CF patients have intact respiratory muscle function and can therefore perform this maneuver. Patients with Motor Neuron Disease suffer from progressive weakness of all muscles including the respiratory muscles. The test results for FVC are affected muscle weakness and are therefore not a valid representation of their pulmonary function.
Outcome measures
| Measure |
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
n=5 Participants
Patients with CF who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
Patients with MND who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
|---|---|---|
|
FVC (% Predicted)
FVC at baseline (% Predicted)
|
68.6 percentage of predicted normal
Standard Deviation 22.09
|
—
|
|
FVC (% Predicted)
FVC after 30 days of therapy (% Predicted)
|
69.8 percentage of predicted normal
Standard Deviation 23.19
|
—
|
|
FVC (% Predicted)
FVC after 90 days of therapy (% Predicted)
|
71.0 percentage of predicted normal
Standard Deviation 21.30
|
—
|
SECONDARY outcome
Timeframe: 90 daysPopulation: FVC and FEV1/FVC ratio are pulmonary function tests appropriate to assess lung function in patients with CF. These tests could not be physically performed by the patients in the MND population and thus these patients were not included in these analysis. For the MND population, SVC, SpO2, MIP, and PCF were performed instead of FVC and FEV1/FVC ratio. Hence, no data were collected from MND patients for this outcome measure.
The proportion of the FVC expired in one second Results are given in both actual values (litres, litres per second) and %predicted-the test result as a percent of the "predicted values" for the patients of similar characteristics. Results over 80% are considered normal. Patients with Motor Neuron Disease suffer from progressive weakness of all muscles including the respiratory muscles. The test results for FVC are affected muscle weakness and are therefore not a valid representation of their pulmonary function.
Outcome measures
| Measure |
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
n=5 Participants
Patients with CF who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
Patients with MND who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
|---|---|---|
|
FEV1/FVC Ratio
FEV1/FVC at baseline
|
78.4 FEV1/FVC ratio
Standard Deviation 19.78
|
—
|
|
FEV1/FVC Ratio
FEV1/FVC after 30 days of therapy
|
81.4 FEV1/FVC ratio
Standard Deviation 18.42
|
—
|
|
FEV1/FVC Ratio
FEV1/FVC after 90 days of therapy
|
82.4 FEV1/FVC ratio
Standard Deviation 14.54
|
—
|
SECONDARY outcome
Timeframe: 90 daysPopulation: FVC and FEV1/FVC ratio are pulmonary function tests appropriate to assess lung function in patients with CF. These tests could not be physically performed by the patients in the MND population and thus these patients were not included in these analysis. For the MND population, SVC, SpO2, MIP, and PCF were performed instead of FVC and FEV1/FVC ratio. Hence, no data were collected from CF patients for this outcome measure.
Slow Vital Capacity (SVC) is the actual volume measured in liters. Slow Vital Capacity displays the volume of gas measured on a complete expiration after a maximal inspiration without forced or rapid effort. Useful measurement when FVC is reduced, and airway obstruction is present. Educed SVC is associated with worsening respiratory disease. Slow Vital Capacity provides the same measure as FVC - i.e. "Vital Capacity." It does not, however, require a "Forced expiratory maneuver (it requires a slow inspiration and slow expiration) and therefore is easier to achieve a valid result in patients with Motor Neuron Disease who suffer from progressive weakness of all muscles including the respiratory muscles.
Outcome measures
| Measure |
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
n=5 Participants
Patients with CF who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
Patients with MND who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
|---|---|---|
|
SVC (Actual)
SVC at baseline (Actual)
|
2.1 Liters
Standard Deviation 0.50
|
—
|
|
SVC (Actual)
SVC after 30 days of therapy (Actual)
|
2.2 Liters
Standard Deviation 0.66
|
—
|
|
SVC (Actual)
SVC after 90 days of therapy (Actual)
|
2.1 Liters
Standard Deviation 0.89
|
—
|
SECONDARY outcome
Timeframe: 90 daysPopulation: FVC and FEV1/FVC ratio are pulmonary function tests appropriate to assess lung function in patients with CF. These tests could not be physically performed by the patients in the MND population and thus these patients were not included in these analysis. For the MND population, SVC, SpO2, MIP, and PCF were performed instead of FVC and FEV1/FVC ratio. Hence, no data were collected from CF patients for this outcome measure.
SVC Percent Predicted (SVC % Predicted) is the actual volume exhaled in the first 1 second, divided by the "Normal" value for that actual value for a person of that age, gender, height and weight. A nomogram based on population norms provides a series of "Normal Values." Slow Vital Capacity displays the volume of gas measured on a complete expiration after a maximal inspiration without forced or rapid effort. Useful measurement when FVC is reduced and airway obstruction is present. Educed SVC is associated with worsening respiratory disease. Slow Vital Capacity provides the same measure as FVC - i.e. "Vital Capacity." It does not, however, require a "Forced expiratory maneuver (it requires a slow inspiration and slow expiration) and therefore is easier to achieve a valid result in patients with Motor Neuron Disease who suffer from progressive weakness of all muscles including the respiratory muscles.
Outcome measures
| Measure |
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
n=5 Participants
Patients with CF who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
Patients with MND who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
|---|---|---|
|
SVC (% Predicted)
SVC at baseline (% Predicted)
|
55.2 percentage of predicted normal
Standard Deviation 13.59
|
—
|
|
SVC (% Predicted)
SVC after 30 days of therapy (% Predicted)
|
58.2 percentage of predicted normal
Standard Deviation 21.10
|
—
|
|
SVC (% Predicted)
SVC after 90 days of therapy (% Predicted)
|
54.6 percentage of predicted normal
Standard Deviation 27.09
|
—
|
SECONDARY outcome
Timeframe: 90 daysPopulation: FVC and FEV1/FVC ratio are pulmonary function tests appropriate to assess lung function in patients with CF. These tests could not be physically performed by the patients in the MND population and thus these patients were not included in these analysis. For the MND population, SVC, SpO2, MIP, and PCF were performed instead of FVC and FEV1/FVC ratio. Hence, no data were collected from CF patients for this outcome measure.
Standard pulmonary function measures (FEV1, FVC, and FEV1/FVC) are commonly followed in the clinical care of patients with CF. Standard pulmonary function measures (SVC, SpO2, MIP, and Peak Cough Flow) are commonly followed in the clinical care of patients with MND. SpO2 stands for peripheral capillary oxygen saturation, an estimate of the amount of oxygen in the blood. Low SpO2 is associated with worsening respiratory function.
Outcome measures
| Measure |
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
n=5 Participants
Patients with CF who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
Patients with MND who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
|---|---|---|
|
SpO2
SpO2 at baseline
|
97.4 Percent of oxygen saturation
Standard Deviation 0.89
|
—
|
|
SpO2
SpO2 after 30 days of therapy
|
96.8 Percent of oxygen saturation
Standard Deviation 1.3
|
—
|
|
SpO2
SpO2 after 90 days of therapy
|
95.8 Percent of oxygen saturation
Standard Deviation 1.64
|
—
|
SECONDARY outcome
Timeframe: 90 daysPopulation: FVC and FEV1/FVC ratio are pulmonary function tests appropriate to assess lung function in patients with CF. These tests could not be physically performed by the patients in the MND population and thus these patients were not included in these analysis. For the MND population, SVC, SpO2, MIP, and PCF were performed instead of FVC and FEV1/FVC ratio. Hence, no data were collected from CF patients for this outcome measure.
Standard pulmonary function measures (FEV1, FVC, and FEV1/FVC) are commonly followed in the clinical care of patients with CF. Standard pulmonary function measures (SVC, SpO2, MIP, and Peak Cough Flow) are commonly followed in the clinical care of patients with MND. Maximal inspiratory pressure (MIP) is a measure of the strength of inspiratory muscles, primarily the diaphragm, and allows for the assessment of ventilatory failure, restrictive lung disease and respiratory muscle strength. Reduction in MIP is asociated with worsening neuromuscular status and poor ability to cough.
Outcome measures
| Measure |
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
n=5 Participants
Patients with CF who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
Patients with MND who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
|---|---|---|
|
Maximal Inspiratory Pressure (MIP)
MIP at baseline
|
-41.0 cmH2O
Standard Deviation 21.24
|
—
|
|
Maximal Inspiratory Pressure (MIP)
MIP after 30 days of therapy
|
-35.6 cmH2O
Standard Deviation 19.65
|
—
|
|
Maximal Inspiratory Pressure (MIP)
MIP at 90 days of therapy
|
-34.8 cmH2O
Standard Deviation 15.32
|
—
|
SECONDARY outcome
Timeframe: 90 daysPopulation: FVC and FEV1/FVC ratio are pulmonary function tests appropriate to assess lung function in patients with CF. These tests could not be physically performed by the patients in the MND population and thus these patients were not included in these analysis. For the MND population, SVC, SpO2, MIP, and PCF were performed instead of FVC and FEV1/FVC ratio. Hence, no data were collected from CF patients for this outcome measure.
Standard pulmonary function measures (FEV1, FVC, and FEV1/FVC) are commonly followed in the clinical care of patients with CF. Standard pulmonary function measures (SVC, SpO2, MIP, and PCF) are commonly followed in the clinical care of patients with MND. The Peak Cough Flow (PCF) is the maximum air flow generated during a cough. Decreasing air flow generated is associated with weakening neuromuscular status and associated poor cough impulse
Outcome measures
| Measure |
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
n=5 Participants
Patients with CF who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
Patients with MND who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.
|
|---|---|---|
|
PCF
PCF at baseline
|
344.0 liters per minute
Standard Deviation 105.74
|
—
|
|
PCF
PCF after 30 days of therapy
|
320.0 liters per minute
Standard Deviation 152.81
|
—
|
|
PCF
PCF after 90 days of therapy
|
280.0 liters per minute
Standard Deviation 144.91
|
—
|
Adverse Events
Patients With CF Treated With Home Based Airway Clearance With Metaneb
Patients With MND Treated With Home Based Airway Clearance With Metaneb
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Baxter Clinical Trials Disclosure Call Center
Baxter Healthcare
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place